Hyder Jinnah

Dr. Hyder Jinnah

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Neuroscience
Verified
Journal Article
Closed access
CPC.N. Prudente
C.N. Prudente
EHE.J. Hess
E.J. Hess
HJHyder Jinnah
Hyder Jinnah

15 June 2013 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
HJHyder Jinnah
Hyder Jinnah
ABAlfredo Berardelli
Alfredo Berardelli
CCCynthia Comella
Cynthia Comella
GDGiovanni Defazio
Giovanni Defazio
MDMahlon R. DeLong
Mahlon R. DeLong
FIfor the Dystonia Coalition Investigators
for the Dystonia Coalition Investigators

22 February 2010 in Brain
Verified
Journal Article
Open access
PDF file
HJHyder Jinnah
Hyder Jinnah
ICIrene Ceballos-Picot
Irene Ceballos-Picot
RTRosa J. Torres
Rosa J. Torres
JVJasper E. Visser
Jasper E. Visser
DSDavid J. Schretlen
David J. Schretlen
FGfor the Lesch-Nyhan Disease International Study Group
for the Lesch-Nyhan Disease International Study Group
Lesch–Nyhan disease is a neurogenetic disorder caused by deficiency of the enzyme hypoxanthine–guanine phosphoribosyltransferase. The classic form of the disease is described by a characteristic syndrome that includes overproduction of uric acid, severe generalized dystonia, cognitive disability and self-injurious behaviour. In addition to the classic disease, variant forms of the disease occur wherein some clinical features are absent or unusually mild. The current studies provide the results of a prospective and multi-centre international study focusing on neurological manifestations of the largest cohort of Lesch–Nyhan disease variants evaluated to date, with 46 patients from 3 to 65 years of age coming from 34 families. All had evidence for overproduction of uric acid. Motor abnormalities were evident in 42 (91%), ranging from subtle clumsiness to severely disabling generalized dystonia. Cognitive function was affected in 31 (67%) but it was never severe. Though none exhibited self-injurious behaviours, many exhibited behaviours that were maladaptive. Only three patients had no evidence of neurological dysfunction. Our results were compared with a comprehensive review of 78 prior reports describing a total of 127 Lesch–Nyhan disease variants. Together these results define the spectrum of clinical features associated with hypoxanthine–guanine phosphoribosyltransferase deficiency. At one end of the spectrum are patients with classic Lesch–Nyhan disease and the full clinical phenotype. At the other end of the spectrum are patients with overproduction of uric acid but no apparent neurological or behavioural deficits. Inbetween are patients with varying degrees of motor, cognitive, or behavioural abnormalities. Recognition of this spectrum is valuable for understanding the pathogenesis and diagnosis of all forms of hypoxanthine–guanine phosphoribosyltransferase deficiency.

1 February 2015 in Neurologic Clinics
Verified
Journal Article
Closed access
HJHyder Jinnah
Hyder Jinnah
SFStewart A. Factor
Stewart A. Factor

22 August 2013 in Brain
Verified
Journal Article
Open access
PDF file
RFRong Fu
Rong Fu
ICIrene Ceballos-Picot
Irene Ceballos-Picot
RTRosa J. Torres
Rosa J. Torres
LLLaura E. Larovere
Laura E. Larovere
YYYasukazu Yamada
Yasukazu Yamada
HJHyder Jinnah
Hyder Jinnah
Establishing meaningful relationships between genetic variations and clinical disease is a fundamental goal for all human genetic disorders. However, these genotype–phenotype correlations remain incompletely characterized and sometimes conflicting for many diseases. Lesch-Nyhan disease is an X-linked recessive disorder that is caused by a wide variety of mutations in the HPRT1 gene. The gene encodes hypoxanthine-guanine phosphoribosyl transferase, an enzyme involved in purine metabolism. The fine structure of enzyme has been established by crystallography studies, and its function can be measured with very precise biochemical assays. This rich knowledge of genetic alterations in the gene and their functional effect on its protein product provides a powerful model for exploring factors that influence genotype–phenotype correlations. The present study summarizes 615 known genetic mutations, their influence on the gene product, and their relationship to the clinical phenotype. In general, the results are compatible with the concept that the overall severity of the disease depends on how mutations ultimately influence enzyme activity. However, careful evaluation of exceptions to this concept point to several additional genetic and non-genetic factors that influence genotype–phenotype correlations. These factors are not unique to Lesch-Nyhan disease, and are relevant to most other genetic diseases. The disease therefore serves as a valuable model for understanding the challenges associated with establishing genotype–phenotype correlations for other disorders.

1 March 2013 in Experimental Neurology
Verified
Journal Article
Closed access
CPC.N. Prudente
C.N. Prudente
CPCarlos A. Pardo-Villamizar
Carlos A. Pardo-Villamizar
JXJianfeng Xiao
Jianfeng Xiao
JHJ. Hanfelt
J. Hanfelt
EHE.J. Hess
E.J. Hess
HJHyder Jinnah
Hyder Jinnah